Braco-19 trihydrochloride(BRAC-O19, BRACO19 3HCl) is a G-quadruplex-stabilizing agent and an inhibitor of telomere/telomerase. It establishes antiviral activity against HIV-1 and anticancer effects by inhibiting telomerase capping and catalytic functions.

Braco-19 trihydrochloride(BRAC-O19, BRACO19 3HCl) is a G-quadruplex-stabilizing agent and an inhibitor of telomere/telomerase. It establishes antiviral activity against HIV-1 and anticancer effects by inhibiting telomerase capping and catalytic functions.

Braco-19 trihydrochloride(BRAC-O19, BRACO19 3HCl) is a G-quadruplex-stabilizing agent and an inhibitor of telomere/telomerase. It establishes antiviral activity against HIV-1 and anticancer effects by inhibiting telomerase capping and catalytic functions.

Braco-19 trihydrochloride(BRAC-O19, BRACO19 3HCl) is a G-quadruplex-stabilizing agent and an inhibitor of telomere/telomerase. It establishes antiviral activity against HIV-1 and anticancer effects by inhibiting telomerase capping and catalytic functions.

Imlunestrant(LY3484356) is a potent, orally bioavailable selective estrogen receptor degrader (SERD) that functions as a pure antagonist of estrogen receptor alpha (ERα). It inhibits ER-dependent gene transcription and cell proliferation, resulting in sustained suppression of estrogen-driven growth in ER-positive cells.

Imlunestrant(LY3484356) is a potent, orally bioavailable selective estrogen receptor degrader (SERD) that functions as a pure antagonist of estrogen receptor alpha (ERα). It inhibits ER-dependent gene transcription and cell proliferation, resulting in sustained suppression of estrogen-driven growth in ER-positive cells.

Imlunestrant(LY3484356) is a potent, orally bioavailable selective estrogen receptor degrader (SERD) that functions as a pure antagonist of estrogen receptor alpha (ERα). It inhibits ER-dependent gene transcription and cell proliferation, resulting in sustained suppression of estrogen-driven growth in ER-positive cells.

Imlunestrant(LY3484356) is a potent, orally bioavailable selective estrogen receptor degrader (SERD) that functions as a pure antagonist of estrogen receptor alpha (ERα). It inhibits ER-dependent gene transcription and cell proliferation, resulting in sustained suppression of estrogen-driven growth in ER-positive cells.

Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.

Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.